ReFacto (Antihemophilic factor [recombinant]) for Hemophilia

Overview
ReFacto is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia A. ReFacto can also be used for perioperative (before, during, and after surgery) care and short-term routine prophylaxis. The technical name of ReFacto is Antihemophilic factor (recombinant).

ReFacto is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that ReFacto is given as an intravenous injection.

ReFacto comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for ReFacto lists common side effects including headache, fever, chills, rash, flushed skin, vomiting, and lethargy.

Rare but serious side effects listed for Refacto include the development of inhibitors.

For more details about this treatment, visit:

ReFacto prescribing information (PDF) – Pfizer

Treatment of Hemophilia – Hemophilia Federation of America